Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

Description

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how drivers of gluconeogenesis and lipemia (specifically measured as visceral fat ratio, insulin resistance, and postprandial lipemia,) that contribute to cardiometabolic risk in T1D change over time.

Conditions

type1diabetes, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how drivers of gluconeogenesis and lipemia (specifically measured as visceral fat ratio, insulin resistance, and postprandial lipemia,) that contribute to cardiometabolic risk in T1D change over time.

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

Condition
type1diabetes
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale Pediatric Diabetes Research, New Haven, Connecticut, United States, 06520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * Male or female, aged 18 to ≤30 years
  • * Diagnosed T1D for at least 12 months and with BMI \<25 kg/m2.
  • * HbA1c ≤10%
  • * Clinical use of continuous glucose monitoring (CGM)
  • * Any known laboratory safety parameter consistently outside the below extended laboratory ranges in the past year:
  • 1. Baseline creatinine \>1.0mg
  • 2. Hypertriglyceridemia (\>400 mg/dl)
  • 3. ALT ≥3.5 times the upper normal limit (UNL)
  • * Current use of adjunctive diabetes medication or anti-obesity medication
  • * Insulin dose \<0.5 units/kg/day
  • * Use of lipid lowering prescription medication other than statins or omega-3 products
  • * Doesn't meet MRI safety criteria or having claustrophobia
  • * Known liver disease other than non-alcoholic steatosis or non-alcoholic fatty liver disease
  • * Known renal impairment
  • * Pregnancy or lactation, or planning to become pregnant during the study period.
  • * Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation.
  • * Treatment with another investigational drug within the past 1 month
  • * Past medical history of or self-reported corn allergy

Ages Eligible for Study

18 Years to 30 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Michelle Van Name, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2028-06